<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04894123</url>
  </required_header>
  <id_info>
    <org_study_id>ACOTAS G-098</org_study_id>
    <nct_id>NCT04894123</nct_id>
  </id_info>
  <brief_title>Cardiovascular Events From Trifluridine/Tipiracil +/- Oxaliplatin in Colorectal/Oesogastric Adenocarcinoma Patients</brief_title>
  <official_title>A Phase II Study Evaluating the Rate of Cardiovascular Events During Trifluridine/Tipiracil +/- Oxaliplatin Treatment in Colorectal/Oesogastric Adenocarcinoma Patients That Have Experienced a Past Episode of Thoracic Angina-related Pain Due to Chemotherapy Including 5-fluorouracil/Capecitabine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Servier</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GERCOR - Multidisciplinary Oncology Cooperative Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess of incidence of cardiovascular events in patients with&#xD;
      esophageal/stomach or colorectal cancer treated by trifluridine/tipiracil +/- oxaliplatin&#xD;
      after an episode of cardiac angina-related thoracic pain in the adjuvant, or metastatic&#xD;
      setting due to fluoropyrimidines&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed about the study and potential risks, all patients giving written&#xD;
      informed consent will undergo a 14-day screening period to determine eligibility for study&#xD;
      entry. Patient who meet the eligibility requirement will be included in the study and will be&#xD;
      treated by trifluridine/tipiracil +/- oxaliplatin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of cardiovascular events</measure>
    <time_frame>at 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE 5.0</measure>
    <time_frame>Assessed up to 48 months</time_frame>
    <description>Safety profile of the trifluridine/tipiracil and oxaliplatin combination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Disease control rate (DCR)</measure>
    <time_frame>Assessed up to 48 months</time_frame>
    <description>DCR defined as partial response, complete response (CR), or stable disease (SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The 3-month drop-out rate of limiting toxicity</measure>
    <time_frame>At 3 months</time_frame>
    <description>Drop-out rate defined as the number of patients who left the study due to limiting toxicity between treatment initiation and 3 months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Colorectal Adenocarcinoma</condition>
  <condition>Oesogastric</condition>
  <arm_group>
    <arm_group_label>trifluridine/tipiracil +/- oxaliplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trifluridine/tipiracil 35 mg/m² orally twice a day from day 1 to day 5 plus oxaliplatin 85 mg/m² intravenous at day 1 every 14 days.&#xD;
If oxaliplatin is stopped for neurotoxicity, allergic reaction or other reason, or it is not indicated, patients will continue trifluridine/tipiracil in monotherapy 35 mg/m² orally twice a day between days 1-5 and days 8-12; repeated every 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trifluridine/Tipiracil</intervention_name>
    <description>Trifluridine/tipiracil : 35 mg/m² orally twice a day from day 1 to day 5 every 14 days.&#xD;
If oxaliplatin is stopped or it is not indicated, trifluridine/tipiracil in monotherapy 35 mg/m² orally twice a day between days 1-5 and days 8-12; repeated every 28 days.</description>
    <arm_group_label>trifluridine/tipiracil +/- oxaliplatin</arm_group_label>
    <other_name>Lonsurf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin : 85 mg/m² intravenous at day 1 every 14 days.</description>
    <arm_group_label>trifluridine/tipiracil +/- oxaliplatin</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Signed and dated informed consent and willingness to comply with all study procedures&#xD;
        and availability for the study duration, 2. Histologically confirmed oeso-gastric, gastric,&#xD;
        colon and/or rectum adenocarcinoma: 3. Patients with metastatic non-resectable (oesogastric&#xD;
        or colorectal) or adjuvant (colorectal stage III) adenocarcinoma previously treated by&#xD;
        fluoropyrimidines (5-FU or capecitabine), 4. Age ≥18 years, 5. Eastern Cooperative Oncology&#xD;
        Group performance status (ECOG PS) of 0-2, 6. Patients who presented an episode of cardiac&#xD;
        angina-related thoracic pain due to 5-FU or capecitabine (minimum 21 days [3 weeks] between&#xD;
        event and inclusion) at least one of the following events:&#xD;
&#xD;
          1. Instable angina,&#xD;
&#xD;
          2. Acute coronary syndrome (ACS) without ST-segment elevation nor troponin rise.&#xD;
             Contraindication to continue treatment with 5FU or capecitabine confirmed and&#xD;
             documented by a cardiologist, 8. Indication to receive trifluridine/tipiracil ±&#xD;
             oxaliplatin considered better than absence of therapy (colo-rectal stage III) or the&#xD;
             best alternative therapy (metastatic colo-rectal and oeso-gastric or gastric)&#xD;
             confirmed by a Multidisciplinary Consultation Meeting, 9. No contraindication to&#xD;
             receive trifluridine/tipiracil (related toxicity), 10. No prior treatment with&#xD;
             trifluridine/tipiracil, 11. Following laboratory values obtained within 14 days (2&#xD;
             weeks) prior to start of study treatment:&#xD;
&#xD;
               -  Hematological status:&#xD;
&#xD;
                    -  absolute neutrophil count (ANC) ≥ 1.5 x 109/L;&#xD;
&#xD;
                    -  platelets ≥ 100 x 109/L;&#xD;
&#xD;
                    -  hemoglobin ≥ 9 g/dL,&#xD;
&#xD;
               -  Adequate renal function:&#xD;
&#xD;
                    -  serum creatinine level &lt; 150 μM&#xD;
&#xD;
                    -  and creatinine clearance ≥ 50 ml/min using the Cockroft-Gault formula,&#xD;
&#xD;
               -  Adequate liver function:&#xD;
&#xD;
                    -  serum total bilirubin ≤ 1.5 x upper limit of normal (ULN),&#xD;
&#xD;
                    -  alkaline phosphatase (ALP) &lt; 5 x ULN,&#xD;
&#xD;
                    -  aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x&#xD;
                       ULN, 12. For female patients of childbearing potential, negative serum&#xD;
                       pregnancy test within 7 days (1 week) prior starting the study treatment,&#xD;
                       13. Female patients of childbearing potential must commit to using reliable&#xD;
                       and effective methods of contraception during the trial and until at least 6&#xD;
                       months after the end of study treatment. Male patients with a partner of&#xD;
                       childbearing potential must agree to use effective contraception in addition&#xD;
                       to the contraceptive method used by their partner during the trial and until&#xD;
                       at least 6 months after the end of study treatment.&#xD;
&#xD;
                       14. Registration in a national health care system (PUMa - Protection&#xD;
                       Universelle Maladie included).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. For metastatic colo-rectal-cancer, MSI and/or dMMR tumor&#xD;
&#xD;
          2. For metastatic oeso-gastric and gastric adenocarcinoma, HER+++ or HER++ FISH positive&#xD;
             tumor&#xD;
&#xD;
          3. Left ventricular dysfunction with a left ventricular ejection fraction (LVEF) &lt; 35%&#xD;
             with or without an automatic implantable defibrillator,&#xD;
&#xD;
          4. Non-revascularized multivessel coronary artery disease,&#xD;
&#xD;
          5. ACS with ST elevation, and/ or troponin rise&#xD;
&#xD;
          6. QT/QTc interval &gt; 470 ms (for women) and &gt; 450 ms (for men) NB: Caution is required&#xD;
             when using medicinal products with human thymidine kinase substrates, e.g. zidovudine&#xD;
             and other drugs known to prolong the QTc interval (exhaustive list on https:&#xD;
             //www.crediblemeds.org.&quot;)&#xD;
&#xD;
          7. Documented coronary vasospasm during 5-FU treatment leading to myocardial infarction,&#xD;
&#xD;
          8. Pregnancy and breastfeeding,&#xD;
&#xD;
          9. Treatment with any other investigational medicinal product within 28 days (4 weeks)&#xD;
             before start of the study treatment,&#xD;
&#xD;
         10. Rare hereditary problems of galactose intolerance, the Lapp lactose deficiency, or&#xD;
             glucose-galactose malabsorption,&#xD;
&#xD;
         11. Any other serious and uncontrolled non-malignant disease,&#xD;
&#xD;
         12. Major surgery or traumatic injury within 28 days (4 weeks) before the start of study&#xD;
             treatment,&#xD;
&#xD;
         13. Patients with known allergy to any excipient to study drugs,&#xD;
&#xD;
         14. Bowel obstruction or inability to swallow tablets,&#xD;
&#xD;
         15. Peripheral neuropathy Grade &gt; 1 for the oxaliplatin schedule,&#xD;
&#xD;
         16. Non resolved non-hematological toxicities from prior therapies (grade &gt;2),&#xD;
&#xD;
         17. Abnormal values at inclusion for :&#xD;
&#xD;
               -  kalemia ;&#xD;
&#xD;
               -  Magnesemia;&#xD;
&#xD;
               -  Calcemia and corrected calcium level&#xD;
&#xD;
         18. Patient under a legal protection regime (guardianship, curatorship, judicial&#xD;
             safeguard), or administrative decision, or incapable of giving his/her consent&#xD;
&#xD;
         19. Impossibility of submitting to the medical follow-up of the study for geographical,&#xD;
             social reasons or psychiatric illness.&#xD;
&#xD;
         20. Patients admitted to a health or social establishment for purposes other than that of&#xD;
             the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Daniel LOPEZ TRABADA, MD</last_name>
    <phone>01 49 28 20 00</phone>
    <email>daniel.lopez-trabada-ataz@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie Line GARCIA</last_name>
    <phone>01 40 29 85 04</phone>
    <email>marie-line.garcia-larnicol@gercor.com.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marine JARY, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marine JARY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Boulogne/ Mer</name>
      <address>
        <city>Boulogne-sur-Mer</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincent BOURGEOIS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vincent BOURGEOIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôptial Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle BAUMGAERTNER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Isabelle BAUMGAERTNER, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Côme LEPAGE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Côme LEPAGE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chloé VERNET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Chloé VERNET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GH Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Baptiste BACHET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean Baptite BACHET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel LOPEZ TRABADA, MD</last_name>
    </contact>
    <investigator>
      <last_name>Daniel LOPEZ TRABADA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David TOUGERON, MD</last_name>
    </contact>
    <investigator>
      <last_name>David TOUGERON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier BOUCHE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olivier BOUCHE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Astrid LIEVRE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Astrid LIEVRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Tours Hôpital Trousseau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thierry LECOMTE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thierry LECOMTE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 16, 2021</study_first_submitted>
  <study_first_submitted_qc>May 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiac toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trifluridine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

